country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-128758

Copy Link Print Information

DYRKs-IN-1

DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 1387090-01-8
Formule: C₃₀H₃₀ClN₇O₄
Masse moléculaire:588.06

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (267 KB)

DYRKs-IN-1 Chemical Structure

CAS No.: 1387090-01-8

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]

DYRK1A

5 nM (IC₅₀)

DYRK1B

8 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform DYRK :

Cellular Effect

Cell Line	Type	Value	Description	References
SW-620	EC₅₀	0.027 μM Compound: 30	Cytotoxicity against human SW620 cells Cytotoxicity against human SW620 cells	[PMID: 24239188]

In Vitro

DYRKs-IN-1 (compound 30) increases the cellular potency against the human colon tumor cell line SW 620 with an EC₅₀ of 27 nM^[1].
DYRKs-IN-1 (Example 183) is a potent DYRKs inhibitor^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1387090-01-8
Masse moléculaire 588.06
Formule C₃₀H₃₀ClN₇O₄
SMILES

O=C(C1=CC2=CN=C(N3CC(O4)CCC4C3)N=C2NC1=O)NC5=CC(C(NC(C6=CC=CC=C6)CCN)=O)=CC=C5Cl
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (267 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Anderson K, et al. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. [Content Brief]

[2]. Kevin Anderson, et al. Pyrido pyrimidines. US20120184542A1.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis